title: [Study of the Ki-67 antibody immunolabeling of renal adenocarcinomas with or without renal vein thrombosis].
abstract: OBJECTIVE
  The objective of this study was to compare the proliferation index (immunolabelling by monoclonal antibody Ki67 - MIB-1) of renal cell carcinomas as a function of the presence or absence of renal vein thrombus. Analysis of the numbers of Ki67-positive nuclei can be used to assess the degree of aggressiveness of the cell populations of these various carcinomas (tumour without thrombus, tumour with thrombus and neoplastic thrombus).
  
  
  METHODS
  Twenty three renal cell carcinomas with renal vein thrombus were matched for Furhman grade (1st degree), tumour volume (2nd degree) and the patient's age (3rd degree) with 23 renal cell carcinomas not presenting any vascular embolus on histology. Monoclonal antibody MIB-1 immunolabelling was performed on 69 paraffin-embedded specimens: 23 tumours with thrombosis, the 23 corresponding neoplastic thrombi and 23 tumours without vascular embolus.
  
  
  RESULTS
  A correlation between Furhman grade and the percentage of immunolabelled nuclei was observed (mean: 2.67% for low-grade tumours and 14.34% for high-grade tumours). No labelling difference was observed between the two populations of primary tumours (with thrombus/without embolus). Primary tumours presented significantly weaker Ki67 labelling than their corresponding neoplastic thrombus (mean of 2.47% versus 10.3%, p < 0.01).
  
  
  CONCLUSIONS
  This study shows that there is no difference of the proliferation index between tumours with neoplastic venous thrombus and those with no histological vascular embolus. However, a difference of proliferation index was observed between the primary tumour and its corresponding thrombus, which presented a statistically higher immunolabelling. This finding suggests that the thrombus possesses more dividing cells than the primary tumour, i.e. has a shorter doubling time.
authors.affiliation: Service d'Urologie, Hôpital Foch, Suresnes, France.
authors.forename: T
authors.initials: T
authors.lastname: Lebret
authors.forename: V
authors.initials: V
authors.lastname: Becette
authors.forename: A
authors.initials: A
authors.lastname: Colau
authors.forename: J M
authors.initials: JM
authors.lastname: Hervé
authors.forename: V
authors.initials: V
authors.lastname: Molinié
authors.forename: P
authors.initials: P
authors.lastname: Barré
authors.forename: P M
authors.initials: PM
authors.lastname: Lugagne-Delpon
authors.forename: A
authors.initials: A
authors.lastname: Gentile
authors.forename: C
authors.initials: C
authors.lastname: Baglin
authors.forename: H
authors.initials: H
authors.lastname: Botto
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis* / Q000601:surgery; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000276:immunology*; D007668:Kidney / Q000276:immunology; D007680:Kidney Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000601:surgery; D008875:Middle Aged; D011379:Prognosis; D012082:Renal Veins; D020246:Venous Thrombosis / Q000175:diagnosis / Q000209:etiology*
chemical_list: D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen